Thought Leader Profile
Shawn Iadonato
CEO, KinetaShawn Iadonato, Ph.D., serves as Kineta's chief executive officer. He is a co-founder of Kineta and previously served as chief scientific officer. Under his leadership as CSO, the Kineta pipeline expanded to include the AviiD™ Screening Platform and five novel drug and vaccine programs with a focus on autoimmune diseases, antivirals, and chronic pain.
Prior to founding Kineta, Shawn co-founded and served as CSO of Illumigen Biosciences Inc. At Illumigen Biosciences, he pioneered its patented drug discovery platform, which relied upon recruitment and screening of healthy populations and elucidation of their shared "wellness" genes. Shawn also led the successful discovery and preclinical development of Illumigen's anti-hepatitis C drug, which ultimately led to the sale of the company in December 2007 to Cubist Pharmaceuticals (now part of Merck & Co.).
Before Illumigen, Shawn managed the Human Genome Center at the University of Washington. He is co-inventor on more than 35 US patents or patent applications. He is principal investigator or co-investigator on numerous ongoing government grants and contracts.
Shawn received a Ph.D. in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.
Speaker at FiRe 2016
Share this: |
News for Shawn Iadonato
-
Posted on Fri Mar 1, 2024, 8:00 am
Kineta CEO included in biotech's latest round of layoffs - Puget Sound - The ... -
Posted on Thu Feb 29, 2024, 8:00 am
Kineta Restructures To Prioritize Cash, Explores Strategic Options - Contract... -
Posted on Thu Feb 29, 2024, 8:00 am
Seattle biotech company Kineta lays off majority of staff, including its CEO ... -
Posted on Thu Aug 17, 2023, 7:00 am
Seattle biotech firm Kineta averts Nasdaq stock delisting - Puget Sound Busin... -
Posted on Mon Oct 17, 2022, 7:00 am
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda - BioSpace -
Posted on Mon Jun 6, 2022, 7:00 am
Seattle biotech Kineta will go public in deal with neurosciences company Yuma... -
Posted on Mon Dec 17, 2018, 8:00 am
Biotech startup Kineta inks cancer deal with Pfizer worth up to $505M - GeekWire -
Posted on Thu May 4, 2017, 7:00 am
Immune Reaction Against Colon Cancer Cells Promoted by RLR Agonists in Study ...